Earnings Outlook For Elevate Credit

Elevate Credit (NYSE:ELVT) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Elevate Credit will report an earnings per share (EPS) of $-0.30.

Elevate Credit (NYSE:ELVT) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here’s what investors need to know before the announcement.

Analysts estimate that Elevate Credit will report an earnings per share (EPS) of $-0.30.

Elevate Credit bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.21, which was followed by a 1.74% drop in the share price the next day.

Here’s a look at Elevate Credit’s past performance and the resulting price change:

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate -0.42 -0.34 -0.37 -0.19
EPS Actual -0.21 -0.44 -0.42 -0.28
Price Change % -1.74% -7.47% -12.02% -2.56%

eps graph

Stock Performance

Shares of Elevate Credit were trading at $1.02 as of November 07. Over the last 52-week period, shares are down 69.62%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Elevate Credit visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Aurora Touts 41% YoY Increase In International Medical Cannabis Q3 Revenue, Expands In Australia Via New Acquisition

Canadian medical cannabis company Aurora Cannabis reported its financial and operational results for Q3 2024. Net revenue increased to CAD64.4m ($42m), up from CAD61.1m in the same quarter the previous year. Medical cannabis net revenue rose by 16% to CAD45.1m, representing 70% of Aurora's consolidated net revenue. Gross profit reached CAD19.8m, up from CAD3.7m in Q3 2022, with adjusted gross profit before fair value adjustments increasing to CAD32.4m from CAD28m. The company recorded a CAD25.5m net loss compared to CAD67.2m in the same quarter in the previous year. Adjusted EBITDA came in at CAD4.3m, up from CAD3m. Miguel Martin, CEO of Aurora, said the company's international medical net revenue had seen year-on-year growth of 41%.

ACB